At the 2025 Society of Surgical Oncology (SSO) Annual Meeting, Dr. Thinzar Min Lwin of City of Hope highlighted two exciting developments in GI cancer surgery: the increasing use of molecular diagnostics, including spatial transcriptomics and multiplex immunohistochemistry, to predict patient outcomes, and City of Hope’s trial of aerosolized intraperitoneal chemotherapy using mitomycin C for peritoneal surface cancers like colorectal and appendiceal carcinomatosis. These innovations could significantly improve prognostication and redefine treatment approaches for patients with advanced GI cancers.
Keep Reading
Add A Comment